News we are keeping an eye on this week includes the FDA’s first traditional market authorization for a COVID-19 test and its approval of a new neurological diagnostic. The agency also updated its device shortage list and revised mammography guidelines.

Sino Biopharm's $161m all-cash acquisition of F-star has finally closed amid heightening US-China tensions and following completion the Chinese firm, through its UK subsidiary invoX, plans to expand its operations and presence at F-star’s UK headquarters.

A temporary reimbursement boost for Shockwave’s C² coronary intravascular lithotripsy (IVL) is coming to an end. John Leppard, Senior Healthcare Analyst & VP at Washington Analysis breaks down what that means for CMS. 

Abbott announced today it plans to integrate its FDA-cleared modified CGMs with insulin pump makers, including Tandem and Insulet, likely later this year.